Optimisation of process strategies in autoinjector development
In the May issue of ONdrug Delivery magazine, SHL Medical’s Markus Goldinger and Erik Alexandersson share their knowledge on SHL’s fully in-house, vertically integrated process development (PD) model and discuss how it benefits the development of the drug delivery device.
The authors argue that a sound PD strategy should be the norm in the autoinjector industry. For SHL Medical, this means having an approach that covers both the upstream and downstream process of combination product development and serves as a “robust anchor” that guides the end-to-end development stream.
The authors further detail SHL’s array of in-sourced capabilities and its close-collaboration with its pharma partners, resulting in a robust process. This overarching PD strategy is reflected through the success of SHL’s Molly® autoinjector projects. Over the years, the Molly® technology has matured to become a modular platform, which coincides with SHL’s PD strategy that ensures quality in the resultant combination product of its customers.
With the ever-changing needs and varying complexities in combination product development, SHL’s solutions in optimising process development strategies are crucial to maintain a sustainable supply chain in the medical device industry. Download the story to learn more about SHL’s process development.
